Results of Phase 1 Trial of Next-Generation Cortisol

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Results of Phase 1 Trial of Next-Generation Cortisol Modulator CORT125134 to Be Presented at Annual Meeting of the American Association of Pharmaceutical Scientists

MENLO PARK, CA--(Marketwired - Oct 13, 2015) - Corcept Therapeutics Incorporated ( NASDAQ : CORT ), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders, announced today that a poster describing the Phase 1 trial results of its next-generation cortisol modulator CORT125134 will be presented at the annual meeting of the American Association of Pharmaceutical Scientists in Orlando, Florida on October 28, 2015.

The poster, entitled " Assessment of Safety, Tolerability, Pharmacokinetics, Proof of Concept and Proof of Pharmacological Effect of Orally Administered CORT125134 Using an Adaptive Clinical Protocol ," will be presented by Quotient Clinical, the Nottingham, UK-based drug development organization that Corcept selected to conduct the trial. For the presentation's precise time and location, visit http://www.quotientclinical.com/events .

Corcept chose Quotient Clinical because of Quotient's ability to carry out formulation development, rapid drug product manufacturing and clinical testing in a single facility. "Quotient's integrated approach to development allowed us to respond to the challenges inherent in clinical trials quickly and cost-effectively," said Dr. Hazel Hunt, Corcept's Vice President of Research. "These capabilities are especially valuable to Corcept as we begin advancing more new compounds to the clinic."

Upcoming Webinar

Dr. Hunt will discuss the design, conduct and outcome of the Phase 1 trial in a webinar hosted by Quotient entitled " Accelerating Timelines from Candidate Selection to Proof-Of-Concept with Enabled-FIH ® Programs ," which will be broadcast at 9:00am, PDT, on October 14, 2015. Dr. Hunt will be joined by Alyson Connor, Quotient Clinical's Executive Director of Exploratory Clinical Pharmacology. For registration and webinar replay information, visit http://www.quotientclincal.com/webinars . 

Corcept's Cortisol Modulation Platform

Corcept's first-generation cortisol modulator, Korlym ® , was approved by the U.S. Food and Drug Administration in 2012 for the treatment of endogenous Cushing's syndrome, an orphan disease that afflicts approximately 20,000 people in the United States. 

CORT125134 is the lead compound in Corcept's portfolio of next-generation cortisol modulators. It was well-tolerated in its Phase 1 trial, where it also demonstrated that it shares Korlym's ability to potently modulate activity at the glucocorticoid receptor, a necessity in treating Cushing's syndrome and a potential treatment for a variety of other metabolic illnesses. When administered in conjunction with chemotherapeutic agents, CORT125134 also slows tumor growth significantly in models of triple negative breasts cancer, castrate resistant prostate cancer and ovarian cancer.

Corcept plans to begin separate Phase 2 trials of CORT125134 for the treatment of Cushing's syndrome and an oncology indication in the first quarter of 2016.

About Korlym ®

Korlym (mifepristone) competitively blocks the glucocorticoid receptor (GR), thereby modulating the effects of excess cortisol in patients with Cushing's syndrome. Since 2012, Corcept has made Korlym available as a once-daily oral treatment of hyperglycemia secondary to endogenous Cushing's syndrome in adult patients with glucose intolerance or diabetes mellitus type 2 who have failed surgery or are not candidates for surgery. Korlym was the first FDA-approved treatment for Cushing's syndrome and the FDA has designated it as an Orphan Drug.

About CORT125134

CORT125134 is a potent modulator of GR, one of the two receptors to which cortisol normally binds, but has no affinity for the progesterone, estrogen, androgen or mineralocorticoid receptors.

About Cushing's Syndrome

Endogenous Cushing's syndrome is caused by prolonged exposure of the body's tissues to high levels of the hormone cortisol and is generated by tumors that produce cortisol or ACTH. Cushing's syndrome is an orphan indication that most commonly affects adults aged 20-50. An estimated 10-15 of every one million people are newly diagnosed with this syndrome each year, resulting in over 3,000 new patients annually in the United States. An estimated 20,000 patients in the United States have Cushing's syndrome, half of whom are cured by surgery. Symptoms vary, but most people have one or more of the following manifestations: high blood sugar, diabetes, high blood pressure, upper body obesity, rounded face, increased fat around the neck, thinning arms and legs, severe fatigue and weak muscles. Irritability, anxiety, cognitive disturbances and depression are also common. Cushing's syndrome can affect every organ system in the body and can be lethal if not treated effectively.

About Quotient Clinical

Quotient Clinical offers unique services -- based on its Translational Pharmaceutics ® platform -- that integrate formulation development, real-time drug product manufacturing and clinical testing, thereby significantly reducing the time and cost of bringing a drug to market. For more than 20 years, Quotient Clinical has brought innovation to drug product development programs for pharmaceutical and biotechnology customers worldwide. The company is based in purpose-built, fully integrated facilities in Nottingham, UK, where formulation development, real-time GMP manufacturing and early clinical trials are performed in the same facility. It employs over 250 staff, offering a full range of support services, from study set-up through to data analysis and reporting.

About Corcept Therapeutics Incorporated

Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders. Korlym, a first generation competitive GR antagonist, is the company's first FDA-approved medication. The company is conducting a Phase 1/2 trial of mifepristone for the treatment of triple-negative breast cancer and is planning Phase 2 studies of CORT125134, one of its next-generation selective GR antagonists, for the treatment of Cushing's syndrome and an oncology indication. The company has developed a proprietary portfolio of other selective GR antagonists that modulate the effects of cortisol, but not progesterone. It owns or has exclusively licensed extensive intellectual property covering the use of GR antagonists, including mifepristone, in the treatment of a wide variety of metabolic, oncologic and psychiatric disorders. It also holds composition of matter patents for its selective GR antagonists.

CONTACT: Charles Robb Chief Financial Officer Corcept Therapeutics 650-688-8783 Email Contact www.corcept.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 371

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 375

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 312

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 122

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 299

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 488

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading

Top 5 Most Recently Viewed Articles

GreenPower Motor Company Aims for Enhanced Growth by Delisting

Updated Category News Views 218

GreenPower Motor Company Announces Delisting Decision GreenPower Motor Company Inc. (NASDAQ: GP) is making a significant move in its growth strategy. The company, which is renowned for manufacturing and distributing all-electric vehicles tailored for medium and heavy-duty applications, has decided to voluntarily delist its shares from the TSX Venture Exchange (the...

Continue Reading
VEON Announces Q4 2024 Trading Update Conference Details

Updated Category News Views 264

VEON Announces Q4 2024 Trading Update Conference Details Dubai – VEON Ltd. (NASDAQ: VEON), a prominent digital operator, has confirmed the upcoming release of significant financial information regarding its fourth quarter and full year ending December 31, 2024. This update will occur around 10:00 GST (2:00 EST) on March 20, 2025. In addition to the financial update,...

Continue Reading
Netcapital's Revenue Fraud Scandal Hits Investor Confidence

Updated Category News Views 206

The Rise and Fall of Netcapital: A Troubling Drop Netcapital Inc. (NASDAQ: NCPL) has found itself in hot water with investors after revelations of a wild scheme to fluff up its revenue figures. It’s like watching a house of cards crumble — and investors are left holding the bag. From December 15, 2021, through September 3, 2026, a slew of misinformation allegedly...

Continue Reading
Honoring Lt. Thomas V. Kelly Jr.: A Hero's Long-Awaited Return

Updated Category News Views 394

Honoring Lt. Thomas V. Kelly Jr.: A Hero's Long-Awaited Return This Memorial Day weekend marks a significant moment in history as the San Francisco East Bay welcomes back a hero after eight decades. The community prepares for a heartfelt homecoming for 2nd Lt. Thomas V. Kelly Jr., who served valiantly as a bombardier during World War II. A Journey Through History Born in...

Continue Reading
TOMY's Zoids Ultrasaurus: Gun for Nostalgia and Growth

Updated Category News Views 28

Unlocking the Power of Nostalgia with TOMY's Ultrasaurus Nostalgia isn't just an emotion; it's a powerful force that can drive sales like nobody's business, and TOMY Company knows this well. They're rolling out the big guns—literally—by adding the animated series' beloved Gravity Cannon to their new AZ-17DX Ultrasaurus model. How's that for a hook? The Gravity Cannon...

Continue Reading